In Vitro and In Vivo Isotope Effects with Hepatitis C Protease Inhibitors: Enhanced Plasma Exposure of Deuterated Telaprevir versus Telaprevir in Rats
Authors:
- 6 November 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (24) , 7993-8001
Abstract
Telaprevir 2 (VX-950), an inhibitor of the hepatitis C virus (HCVa) NS3-4A protease, is in phase 3 clinical trials. One of the major metabolites of 2 is its P1-(R)-diastereoisomer, 3 (VRT-394), containing an inversion at the chiral center next to the α-ketoamide on exchange of a proton with solvent. Compound 3 is approximately 30-fold less active against HCV protease. In an attempt to suppress the epimerization of 2 without losing activity against the HCV protease, the proton at that chiral site was replaced with deuterium (d). The compound 1 (d-telaprevir) is as efficacious as 2 in in vitro inhibition of protease activity and viral replication (replicon) assays. The kinetics of in vitro stability of 1 and 2 in buffered pH solutions and plasma samples, including human plasma, suggest that 1 is significantly more stable than 2. Oral administration (10 mg/kg) in rats resulted in a ∼13% increase of AUC for 1.Keywords
This publication has 22 references indexed in Scilit:
- HCV NS5B Polymerase InhibitorsClinics in Liver Disease, 2009
- Serine protease inhibitors as anti-hepatitis C virus agentsExpert Review of Anti-infective Therapy, 2009
- Current and future treatment options for HCVAnnals of Hepatology, 2009
- Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infectionExpert Opinion on Therapeutic Patents, 2009
- Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized StudyGastroenterology, 2006
- Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine ProteaseAntimicrobial Agents and Chemotherapy, 2006
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Hepatitis C: an epidemiological reviewJournal of Viral Hepatitis, 2002
- Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In VivoJournal of Virology, 2000